{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T10:16:03Z","timestamp":1792145763708,"version":"4.4.0"},"reference-count":38,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T00:00:00Z","timestamp":1771977600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003348","name":"Fukuda Foundation for Medical Technology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003348","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008884","name":"Nakatani Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008884","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Advancement of Measuring Technologies in Biomedical Engineering"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,4,30]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>The European Society of Cardiology guidelines recommend low-density lipoprotein cholesterol (LDL-C) &amp;lt; 55\u2005mg\/dL in very-high-risk patients. Given that plaque phenotype underscores its modulatory response to lipid-lowering therapies, patients and lesions harbouring lipid-laden plaques may benefit from LDL-C &amp;lt; 55\u2005mg\/dL to reduce their cardiovascular risks.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>The REASSURE-NIRS (REvelation of PAthophySiological PhenotypeS of VUlneRable Lipid-Rich PlaquE on Near-InfraRed Spectroscopy) multi-centre registry enrolled 853 coronary artery disease patients (non-culprit lesions = 1662) receiving NIRS\/IVUS-guided PCI (NCT04864171). LDL-C level at 3 months after PCI was used as on-treatment LDL-C. Study subjects were stratified according to maxLCBI4mm at non-culprit lesions &amp;lt; vs. \u2265324.7. In each group, major adverse cardiac events (MACE) (=cardiac-cause death + non-fatal myocardial infarction (MI) + ischaemia-driven non-culprit lesion revascularization) was compared in those with on-treatment LDL-C &amp;lt; vs. \u226555\u2005mg\/dL. 31.6% of study subjects achieved on-treatment LDL-C &amp;lt; 55\u2005mg\/dL. During the observational period (median = 1109 days), MACE rate did not differ in patients with maxLCBI4mm &amp;lt; 324.7 exhibiting on-treatment LDL-C levels &amp;lt; and \u226555\u2005mg\/dL [adjusted hazard ratio (HR) = 1.42, 95% confidence interval (CI) = 0.80\u20132.54, P = 0.227]. By contrast, in patients with non-culprit lesion maxLCBI4mm \u2265 324.7, a significantly reduced MACE rate was observed in those with on-treatment LDL-C &amp;lt; 55\u2005mg\/dL (adjusted HR = 0.23, 95% CI: 0.09\u20130.57, P = 0.010). These relationships were similarly observed in a lesion-based analysis (non-culprit lesion maxLCBI4mm &amp;lt; 324.7: adjusted HR = 1.30, 95% CI = 0.42\u20134.00, P = 0.640, non-culprit lesion maxLCBI4mm \u2265 324.7: adjusted HR = 0.27, 95% CI:0.08\u20130.97, P = 0.045). Notably, in patients with multiple non-culprit lesions with maxLCBI4mm \u2265 324.7, on-treatment LDL-C &amp;lt; 55\u2005mg\/dL was associated with a lower frequency of MACE (adjusted HR = 0.22, 95% CI = 0.09\u20130.53, P &amp;lt; 0.001), whereas this relationship was not observed in those with single non-culprit lesion with maxLCBI4mm \u2265 324.7 (adjusted HR = 0.03, 95% CI = 0.00\u20135.55, P = 0.196).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>NIRS-derived lipid-rich plaque may be a potential imaging measure reflecting patients and lesions that may benefit from achieving LDL-C levels &amp;lt; 55\u2005mg\/dL.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ehjci\/jeag057","type":"journal-article","created":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T12:43:39Z","timestamp":1771591419000},"page":"998-1011","source":"Crossref","is-referenced-by-count":4,"title":["Achieved LDL-C levels &amp;lt;55\u2005mg\/dL and cardiac events in patients and lesions harbouring lipid-rich plaque phenotypes"],"prefix":"10.1093","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6307-5593","authenticated-orcid":false,"given":"Yu","family":"Kataoka","sequence":"first","affiliation":[{"name":"Department of Cardiovascular Medicine, National Cerebral & Cardiovascular Center , 6-1 Kishibe-shinmachi, Suita, Osaka 5648565 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen J","family":"Nicholls","sequence":"additional","affiliation":[{"name":"Monash Heart, Monash University , Clayton, Victoria ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eri","family":"Kiyoshige","sequence":"additional","affiliation":[{"name":"Department of Preventive Cardiology, National Cerebral & Cardiovascular Center , Suita, Osaka ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kunihiro","family":"Nishimura","sequence":"additional","affiliation":[{"name":"Department of Preventive Cardiology, National Cerebral & Cardiovascular Center , Suita, Osaka ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8849-7426","authenticated-orcid":false,"given":"Rishi","family":"Puri","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Cleveland Clinic , Cleveland, OH ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6073-1302","authenticated-orcid":false,"given":"Satoshi","family":"Kitahara","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Kashiwa Kosei General Hospital , Kashiwa, Chiba ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5162-4783","authenticated-orcid":false,"given":"Kota","family":"Murai","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, National Cerebral & Cardiovascular Center , 6-1 Kishibe-shinmachi, Suita, Osaka 5648565 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kentaro","family":"Mitsui","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, National Cerebral & Cardiovascular Center , 6-1 Kishibe-shinmachi, Suita, Osaka 5648565 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiyuki","family":"Tomishima","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, National Cerebral & Cardiovascular Center , 6-1 Kishibe-shinmachi, Suita, Osaka 5648565 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenichiro","family":"Sawada","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, National Cerebral & Cardiovascular Center , 6-1 Kishibe-shinmachi, Suita, Osaka 5648565 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideo","family":"Matama","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, National Cerebral & Cardiovascular Center , 6-1 Kishibe-shinmachi, Suita, Osaka 5648565 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takamasa","family":"Iwai","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, National Cerebral & Cardiovascular Center , 6-1 Kishibe-shinmachi, Suita, Osaka 5648565 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Honda","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, National Cerebral & Cardiovascular Center , 6-1 Kishibe-shinmachi, Suita, Osaka 5648565 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhiro","family":"Nakao","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, National Cerebral & Cardiovascular Center , 6-1 Kishibe-shinmachi, Suita, Osaka 5648565 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2706-4317","authenticated-orcid":false,"given":"Masashi","family":"Fujino","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, National Cerebral & Cardiovascular Center , 6-1 Kishibe-shinmachi, Suita, Osaka 5648565 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kensuke","family":"Takagi","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, National Cerebral & Cardiovascular Center , 6-1 Kishibe-shinmachi, Suita, Osaka 5648565 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuichi","family":"Yoneda","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, National Cerebral & Cardiovascular Center , 6-1 Kishibe-shinmachi, Suita, Osaka 5648565 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumiyuki","family":"Otsuka","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, National Cerebral & Cardiovascular Center , 6-1 Kishibe-shinmachi, Suita, Osaka 5648565 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1718-3830","authenticated-orcid":false,"given":"Kensaku","family":"Nishihira","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Miyazaki Medical Association Hospital , Miyazaki ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Itaru","family":"Takamisawa","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Sakakibara Heart Institute , Fuchu, Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9009-7234","authenticated-orcid":false,"given":"Yasuhide","family":"Asaumi","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, National Cerebral & Cardiovascular Center , 6-1 Kishibe-shinmachi, Suita, Osaka 5648565 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5372-4932","authenticated-orcid":false,"given":"Teruo","family":"Noguchi","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, National Cerebral & Cardiovascular Center , 6-1 Kishibe-shinmachi, Suita, Osaka 5648565 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,2,25]]},"reference":[{"key":"2026042919573685500_jeag057-B1","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk","volume":"41","author":"Mach","year":"2020","journal-title":"Eur Heart J"},{"key":"2026042919573685500_jeag057-B2","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","article-title":"Ezetimibe added to statin therapy after acute coronary syndromes","volume":"372","author":"Cannon","year":"2015","journal-title":"N Engl J Med"},{"key":"2026042919573685500_jeag057-B3","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N Engl J Med"},{"key":"2026042919573685500_jeag057-B4","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","article-title":"Alirocumab and cardiovascular outcomes after acute coronary syndrome","volume":"379","author":"Schwartz","year":"2018","journal-title":"N Engl J Med"},{"key":"2026042919573685500_jeag057-B5","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1093\/eurjpc\/zwaa047","article-title":"EU-Wide Cross-Sectional observational study of lipid-modifying therapy use in secondary and primary care: the DA VINCI study","volume":"28","author":"Ray","year":"2021","journal-title":"Eur J Prev Cardiol"},{"key":"2026042919573685500_jeag057-B6","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1056\/NEJMoa1110874","article-title":"Effect of two intensive statin regimens on progression of coronary disease","volume":"365","author":"Nicholls","year":"2011","journal-title":"N Engl J Med"},{"key":"2026042919573685500_jeag057-B7","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1001\/jama.2016.16951","article-title":"Effect of evolocumab on progression of coronary disease in statin-treated patients: the GLAGOV Randomized Clinical Trial","volume":"316","author":"Nicholls","year":"2016","journal-title":"JAMA"},{"key":"2026042919573685500_jeag057-B8","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1016\/j.jcmg.2022.03.002","article-title":"Effect of evolocumab on coronary plaque phenotype and burden in statin-treated patients following myocardial infarction","volume":"15","author":"Nicholls","year":"2022","journal-title":"JACC Cardiovasc Imaging"},{"key":"2026042919573685500_jeag057-B9","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1001\/jama.2022.5218","article-title":"Effect of alirocumab added to high-intensity statin therapy on coronary atherosclerosis in patients with acute myocardial infarction: the PACMAN-AMI Randomized Clinical Trial","volume":"327","author":"R\u00e4ber","year":"2022","journal-title":"JAMA"},{"key":"2026042919573685500_jeag057-B10","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.jacc.2006.10.038","article-title":"Coronary artery calcification and changes in atheroma burden in response to established medical therapies","volume":"49","author":"Nicholls","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"2026042919573685500_jeag057-B11","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1016\/j.jacc.2012.03.012","article-title":"Spotty calcification as a marker of accelerated progression of coronary atherosclerosis: insights from serial intravascular ultrasound","volume":"59","author":"Kataoka","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"2026042919573685500_jeag057-B12","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1016\/S0140-6736(19)31794-5","article-title":"Identification of patients and plaques vulnerable to future coronary events with near-infrared spectroscopy intravascular ultrasound imaging: a prospective, cohort study","volume":"394","author":"Waksman","year":"2019","journal-title":"Lancet"},{"key":"2026042919573685500_jeag057-B13","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1016\/S0140-6736(21)00249-X","article-title":"Identification of vulnerable plaques and patients by intracoronary near-infrared spectroscopy and ultrasound (PROSPECT II): a prospective natural history study","volume":"397","author":"Erlinge","year":"2021","journal-title":"Lancet"},{"key":"2026042919573685500_jeag057-B14","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1253\/circj.CJ-21-1041","article-title":"JCS 2022 guideline focused update on diagnosis and treatment in patients with stable coronary artery disease","volume":"86","author":"Nakano","year":"2022","journal-title":"Circ J"},{"key":"2026042919573685500_jeag057-B15","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1253\/circj.CJ-19-0133","article-title":"JCS 2018 guideline on diagnosis and treatment of acute coronary syndrome","volume":"83","author":"Kimura","year":"2019","journal-title":"Circ J"},{"key":"2026042919573685500_jeag057-B16","doi-asserted-by":"crossref","first-page":"846","DOI":"10.5551\/jat.GL2017","article-title":"Japan Atherosclerosis Society (JAS) guidelines for prevention of atherosclerotic cardiovascular diseases 2017","volume":"25","author":"Kinoshita","year":"2018","journal-title":"J Atheroscler Thromb"},{"key":"2026042919573685500_jeag057-B17","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s13340-020-00439-5","article-title":"Japanese clinical practice guideline for diabetes 2019","volume":"11","author":"Araki","year":"2020","journal-title":"Diabetol Int"},{"key":"2026042919573685500_jeag057-B18","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/j.jacc.2011.09.077","article-title":"Functional measurement of coronary stenosis","volume":"59","author":"Pijls","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"2026042919573685500_jeag057-B19","first-page":"e18","article-title":"2021 ACC\/AHA\/SCAI guideline for coronary artery revascularization: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"145","author":"Lawton","year":"2022","journal-title":"Circulation"},{"key":"2026042919573685500_jeag057-B20","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1093\/eurheartj\/ehy394","article-title":"2018 ESC\/EACTS guidelines on myocardial revascularization","volume":"40","author":"Neumann","year":"2019","journal-title":"Eur Heart J"},{"key":"2026042919573685500_jeag057-B21","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1253\/circj.CJ-19-1131","article-title":"JCS 2018 guideline on diagnosis of chronic coronary heart diseases","volume":"85","author":"Yamagishi","year":"2021","journal-title":"Circ J"},{"key":"2026042919573685500_jeag057-B22","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1016\/j.jacc.2023.08.019","article-title":"Concomitant coronary atheroma regression and stabilization in response to lipid-lowering therapy","volume":"82","author":"Biccir\u00e8","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"2026042919573685500_jeag057-B23","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1093\/ehjci\/jeu169","article-title":"The relationship among extent of lipid-rich plaque, lesion characterstics, and plaque progression\/regression in patients with coronary artery disease: a serial near-infrared spectroscopy and intravascular ultrasound","volume":"16","author":"Dohi","year":"2015","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"2026042919573685500_jeag057-B24","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1056\/NEJMra1216063","article-title":"Mechanisms of acute coronary syndromes and their implications for therapy","volume":"368","author":"Libby","year":"2013","journal-title":"N Engl J Med"},{"key":"2026042919573685500_jeag057-B25","doi-asserted-by":"crossref","first-page":"2491","DOI":"10.1016\/j.jacc.2014.01.054","article-title":"Innate and adaptive inflammation as a therapeutic target in vascular disease: the emerging role of statins","volume":"63","author":"Tousoulis","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"2026042919573685500_jeag057-B26","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1093\/cvr\/cvad083","article-title":"Cardiovascular complications in chronic kidney disease: a review from the European Renal and Cardiovascular Medicine Working Group of the European Renal Association","volume":"119","author":"Zoccali","year":"2023","journal-title":"Cardiovasc Res"},{"key":"2026042919573685500_jeag057-B27","doi-asserted-by":"crossref","first-page":"zwaf649","DOI":"10.1093\/eurjpc\/zwaf649","article-title":"Clinical significance of elevated lipoprotein(a) in primary and secondary prevention: a multi-institutional study","author":"Chen","year":"2025","journal-title":"Eur J Prev Cardiol"},{"key":"2026042919573685500_jeag057-B28","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1016\/j.jacc.2025.02.032","article-title":"Prevalence of elevated lipoprotein(a) and its association with subclinical atherosclerosis in 2.9 million Chinese adults","volume":"85","author":"Man","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"2026042919573685500_jeag057-B29","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1016\/j.jcin.2021.07.042","article-title":"Association of lipoprotein(a) with recurrent ischemic events following percutaneous coronary intervention","volume":"14","author":"Yoon","year":"2021","journal-title":"JACC Cardiovasc Interv"},{"key":"2026042919573685500_jeag057-B30","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/S0140-6736(24)01308-4","article-title":"Lipoprotein(a) and cardiovascular disease","volume":"404","author":"Nordestgaard","year":"2024","journal-title":"Lancet"},{"key":"2026042919573685500_jeag057-B31","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/j.jacc.2022.06.019","article-title":"Ancestry, lipoprotein(a), and cardiovascular risk thresholds: JACC review topic of the week","volume":"80","author":"Tsimikas","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"2026042919573685500_jeag057-B32","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1681\/ASN.V61110","article-title":"Multicenter study of lipoprotein(a) and apolipoprotein(a) phenotypes in patients with end-stage renal disease treated by hemodialysis or continuous ambulatory peritoneal dialysis","volume":"6","author":"Kronenberg","year":"1995","journal-title":"J Am Soc Nephrol"},{"key":"2026042919573685500_jeag057-B33","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1194\/jlr.R083626","article-title":"The role of lipoprotein(a) in chronic kidney disease","volume":"59","author":"Hopewell","year":"2018","journal-title":"J Lipid Res"},{"key":"2026042919573685500_jeag057-B34","doi-asserted-by":"crossref","first-page":"100624","DOI":"10.1016\/j.lanepe.2023.100624","article-title":"Treatment gaps in the implementation of LDL cholesterol control among high- and very high-risk patients in Europe between 2020 and 2021: the multinational observational SANTORINI study","volume":"29","author":"Ray","year":"2023","journal-title":"Lancet Reg Health Eur"},{"key":"2026042919573685500_jeag057-B35","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.ahj.2024.06.012","article-title":"Achievement of LDL-C&lt;55 mg\/dL among US adults: findings from the cvMOBIUS2 registry","volume":"279","author":"Navar","year":"2025","journal-title":"Am Heart J"},{"key":"2026042919573685500_jeag057-B36","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.atherosclerosis.2021.08.035","article-title":"Lipid-lowering therapy use in primary and secondary care in Central and Eastern Europe: DA VINCI observational study","volume":"334","author":"Vrablik","year":"2021","journal-title":"Atherosclerosis"},{"key":"2026042919573685500_jeag057-B37","doi-asserted-by":"crossref","first-page":"100665","DOI":"10.1016\/j.lanepe.2023.100665","article-title":"Optimal implementation of the 2019 ESC\/EAS dyslipidaemia guidelines in patients with and without atherosclerotic cardiovascular disease across Europe: a simulation based on the DA VINCI study","volume":"31","author":"Brandts","year":"2023","journal-title":"Lancet Reg Health Eur"},{"key":"2026042919573685500_jeag057-B38","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/j.jcmg.2021.11.014","article-title":"Determinants of plaque progression despite very low low-density lipoprotein-cholesterol levels with the PCSK9 inhibitor, evolocumab","volume":"15","author":"Honda","year":"2022","journal-title":"JACC Cardiovasc Imaging"}],"container-title":["European Heart Journal - Cardiovascular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ehjcimaging\/advance-article-pdf\/doi\/10.1093\/ehjci\/jeag057\/67107473\/jeag057.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjcimaging\/article-pdf\/27\/5\/998\/67107473\/jeag057.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjcimaging\/article-pdf\/27\/5\/998\/67107473\/jeag057.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T23:57:50Z","timestamp":1777507070000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ehjcimaging\/article\/27\/5\/998\/8497209"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,25]]},"references-count":38,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,2,25]]},"published-print":{"date-parts":[[2026,4,30]]}},"URL":"https:\/\/doi.org\/10.1093\/ehjci\/jeag057","relation":{},"ISSN":["2047-2404","2047-2412"],"issn-type":[{"value":"2047-2404","type":"print"},{"value":"2047-2412","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,5]]},"published":{"date-parts":[[2026,2,25]]}}}